In view of the lack of a treatment strategy of cancer patients infected with COVID-19 as well as the reasonable rationale of utilizing galectin-3 as a novel therapeutic target, we have investigated the role and possible regulatory mechanisms of Gal-3 in ICC. The gene discussed is LGALS3; the disease is COVID-19.